Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Adicionar filtros

Base de dados
Tipo de documento
Intervalo de ano
1.
Sarah Wulf Hanson; Cristiana Abbafati; Joachim G Aerts; Ziyad Al-Aly; Charlie Ashbaugh; Tala Ballouz; Oleg Blyuss; Polina Bobkova; Gouke Bonsel; Svetlana Borzakova; Danilo Buonsenso; Denis Butnaru; Austin Carter; Helen Chu; Cristina De Rose; Mohamed Mustafa Diab; Emil Ekbom; Maha El Tantawi; Victor Fomin; Robert Frithiof; Aysylu Gamirova; Petr V Glybochko; Juanita A. Haagsma; Shaghayegh Haghjooy Javanmard; Erin B Hamilton; Gabrielle Harris; Majanka H Heijenbrok-Kal; Raimund Helbok; Merel E Hellemons; David Hillus; Susanne M Huijts; Michael Hultstrom; Waasila Jassat; Florian Kurth; Ing-Marie Larsson; Miklos Lipcsey; Chelsea Liu; Callan D Loflin; Andrei Malinovschi; Wenhui Mao; Lyudmila Mazankova; Denise McCulloch; Dominik Menges; Noushin Mohammadifard; Daniel Munblit; Nikita A Nekliudov; Osondu Ogbuoji; Ismail M Osmanov; Jose L. Penalvo; Maria Skaalum Petersen; Milo A Puhan; Mujibur Rahman; Verena Rass; Nickolas Reinig; Gerard M Ribbers; Antonia Ricchiuto; Sten Rubertsson; Elmira Samitova; Nizal Sarrafzadegan; Anastasia Shikhaleva; Kyle E Simpson; Dario Sinatti; Joan B Soriano; Ekaterina Spiridonova; Fridolin Steinbeis; Andrey A Svistunov; Piero Valentini; Brittney J van de Water; Rita van den Berg-Emons; Ewa Wallin; Martin Witzenrath; Yifan Wu; Hanzhang Xu; Thomas Zoller; Christopher Adolph; James Albright; Joanne O Amlag; Aleksandr Y Aravkin; Bree L Bang-Jensen; Catherine Bisignano; Rachel Castellano; Emma Castro; Suman Chakrabarti; James K Collins; Xiaochen Dai; Farah Daoud; Carolyn Dapper; Amanda Deen; Bruce B Duncan; Megan Erickson; Samuel B Ewald; Alize J Ferrari; Abraham D. Flaxman; Nancy Fullman; Amiran Gamkrelidze; John R Giles; Gaorui Guo; Simon I Hay; Jiawei He; Monika Helak; Erin N Hulland; Maia Kereselidze; Kris J Krohn; Alice Lazzar-Atwood; Akiaja Lindstrom; Rafael Lozano; Beatrice Magistro; Deborah Carvalho Malta; Johan Mansson; Ana M Mantilla Herrera; Ali H Mokdad; Lorenzo Monasta; Shuhei Nomura; Maja Pasovic; David M Pigott; Robert C Reiner Jr.; Grace Reinke; Antonio Luiz P Ribeiro; Damian Francesco Santomauro; Aleksei Sholokhov; Emma Elizabeth Spurlock; Rebecca Walcott; Ally Walker; Charles Shey Wiysonge; Peng Zheng; Janet Prvu Bettger; Christopher JL Murray; Theo Vos.
medrxiv; 2022.
Preprint em Inglês | medRxiv | ID: ppzbmed-10.1101.2022.05.26.22275532

RESUMO

ImportanceWhile much of the attention on the COVID-19 pandemic was directed at the daily counts of cases and those with serious disease overwhelming health services, increasingly, reports have appeared of people who experience debilitating symptoms after the initial infection. This is popularly known as long COVID. ObjectiveTo estimate by country and territory of the number of patients affected by long COVID in 2020 and 2021, the severity of their symptoms and expected pattern of recovery DesignWe jointly analyzed ten ongoing cohort studies in ten countries for the occurrence of three major symptom clusters of long COVID among representative COVID cases. The defining symptoms of the three clusters (fatigue, cognitive problems, and shortness of breath) are explicitly mentioned in the WHO clinical case definition. For incidence of long COVID, we adopted the minimum duration after infection of three months from the WHO case definition. We pooled data from the contributing studies, two large medical record databases in the United States, and findings from 44 published studies using a Bayesian meta-regression tool. We separately estimated occurrence and pattern of recovery in patients with milder acute infections and those hospitalized. We estimated the incidence and prevalence of long COVID globally and by country in 2020 and 2021 as well as the severity-weighted prevalence using disability weights from the Global Burden of Disease study. ResultsAnalyses are based on detailed information for 1906 community infections and 10526 hospitalized patients from the ten collaborating cohorts, three of which included children. We added published data on 37262 community infections and 9540 hospitalized patients as well as ICD-coded medical record data concerning 1.3 million infections. Globally, in 2020 and 2021, 144.7 million (95% uncertainty interval [UI] 54.8-312.9) people suffered from any of the three symptom clusters of long COVID. This corresponds to 3.69% (1.38-7.96) of all infections. The fatigue, respiratory, and cognitive clusters occurred in 51.0% (16.9-92.4), 60.4% (18.9-89.1), and 35.4% (9.4-75.1) of long COVID cases, respectively. Those with milder acute COVID-19 cases had a quicker estimated recovery (median duration 3.99 months [IQR 3.84-4.20]) than those admitted for the acute infection (median duration 8.84 months [IQR 8.10-9.78]). At twelve months, 15.1% (10.3-21.1) continued to experience long COVID symptoms. Conclusions and relevanceThe occurrence of debilitating ongoing symptoms of COVID-19 is common. Knowing how many people are affected, and for how long, is important to plan for rehabilitative services and support to return to social activities, places of learning, and the workplace when symptoms start to wane. Key PointsO_ST_ABSQuestionC_ST_ABSWhat are the extent and nature of the most common long COVID symptoms by country in 2020 and 2021? FindingsGlobally, 144.7 million people experienced one or more of three symptom clusters (fatigue; cognitive problems; and ongoing respiratory problems) of long COVID three months after infection, in 2020 and 2021. Most cases arose from milder infections. At 12 months after infection, 15.1% of these cases had not yet recovered. MeaningThe substantial number of people with long COVID are in need of rehabilitative care and support to transition back into the workplace or education when symptoms start to wane.


Assuntos
Doença Aguda , Dispneia , COVID-19 , Fadiga , Transtornos Cognitivos , Doença
2.
medrxiv; 2021.
Preprint em Inglês | medRxiv | ID: ppzbmed-10.1101.2021.10.01.21264385

RESUMO

Background: Throughout the coronavirus disease 2019 (COVID-19) pandemic, there have been a variety of practices for international reporting of COVID-19 data. African countries have used different national reporting systems to publicly share data. Analyzing the content, format, and frequency of these systems could elucidate lessons for future pandemics. Methods: We examined national COVID-19 reporting practices across 54 African countries through 2020. Reporting systems were compared by type of report, frequency, and data content. We also compared reporting of metrics such as a patient demographics and co-morbidities, healthcare capacity, and diagnostic testing. We further evaluated regional and country-specific reporting practices in Cameroon, Egypt, Kenya, Senegal, and South Africa as examples from different sub-regions. Results: National COVID-19 reporting systems were identified in 53/54 (98.1%) countries in 2020. Reporting systems were diverse and could be categorized into social media postings, websites, press releases, situation reports, and online dashboards. Of countries with reporting systems, 36/53 (67.9%) had recurrent situation reports and/or online dashboards which provided the highest quality of data. Conclusions: African countries created diverse reporting systems to share COVID-19 data. Many countries used routinely updated situation reports or online dashboards. However, few countries reported patient demographics, co-morbidities, diagnostic testing practices, and healthcare capacity. Including these metrics as well as improving standardization and accessibility of data reporting systems could augment research and decision-making, as well as increase public awareness and transparency for national governments.


Assuntos
COVID-19
3.
medrxiv; 2020.
Preprint em Inglês | medRxiv | ID: ppzbmed-10.1101.2020.07.13.20151233

RESUMO

Background: Forecasts and alternative scenarios of the COVID-19 pandemic have been critical inputs into a range of important decisions by healthcare providers, local and national government agencies and international organizations and actors. Hundreds of COVID-19 models have been released. Decision-makers need information about the predictive performance of these models to help select which ones should be used to guide decision-making. Methods: We identified 383 published or publicly released COVID-19 forecasting models. Only seven models met the inclusion criteria of: estimating for five or more countries, providing regular updates, forecasting at least 4 weeks from the model release date, estimating mortality, and providing date-versioned sets of previously estimated forecasts. These models included those produced by: DELPHI-MIT (Delphi), Youyang Gu (YYG), the Los Alamos National Laboratory (LANL), Imperial College London (Imperial), and three models produced by the Institute for Health Metrics and Evaluation (IHME). For each of these models, we examined the median absolute percent error-compared to subsequently observed trends-for weekly and cumulative death forecasts. Errors were stratified by weeks of extrapolation, world region, and month of model estimation. For locations with epidemics showing a clear peak, each model's accuracy was also evaluated in predicting the timing of peak daily mortality. Results: Across models, the median absolute percent error (MAPE) on cumulative deaths for models released in June rose with increased weeks of extrapolation, from 2.3% at one week to 16.3% at six weeks. MAPE at 6 weeks was less than 20% for the IHME-MS-SEIR model (10.2%), YYG (11.1%), LANL (12.6%) and Delphi (19.1%). Across models, MAPE at six weeks were the highest in Sub-Saharan Africa (65.3%), and the lowest in high-income countries (8.5%). Median absolute errors (MAE) for peak timing also rose with increased forecasting weeks, from 9 days at one week to 30 days at six weeks. Peak timing MAE at six weeks ranged from 20 days for the IHME Curve Fit model, to 38 days for the LANL model. Interpretation: Four of the models, from IHME, YYG, Delphi and LANL, had less than 20% MAPE at six weeks. Despite the complexities of modelling human behavioural responses and government interventions related to COVID-19, predictions among these better-performing models were surprisingly accurate. Forecasts and alternative scenarios can be a useful input to decision-makers, although users should be aware of increasing errors with a greater amount of extrapolation time, and corresponding steadily widening uncertainty intervals further in the future. The framework and publicly available codebase presented can be routinely used to evaluate the performance of all publicly released models meeting inclusion criteria in the future, and compare current model predictions.


Assuntos
COVID-19
4.
medrxiv; 2020.
Preprint em Inglês | medRxiv | ID: ppzbmed-10.1101.2020.03.02.20026708

RESUMO

The ongoing COVID-19 outbreak has expanded rapidly throughout China. Major behavioral, clinical, and state interventions are underway currently to mitigate the epidemic and prevent the persistence of the virus in human populations in China and worldwide. It remains unclear how these unprecedented interventions, including travel restrictions, have affected COVID-19 spread in China. We use real-time mobility data from Wuhan and detailed case data including travel history to elucidate the role of case importation on transmission in cities across China and ascertain the impact of control measures. Early on, the spatial distribution of COVID-19 cases in China was well explained by human mobility data. Following the implementation of control measures, this correlation dropped and growth rates became negative in most locations, although shifts in the demographics of reported cases are still indicative of local chains of transmission outside Wuhan. This study shows that the drastic control measures implemented in China have substantially mitigated the spread of COVID-19.


Assuntos
COVID-19
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA